Page last updated: 2024-11-02

oxidopamine and Blindness

oxidopamine has been researched along with Blindness in 1 studies

Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).

Blindness: The inability to see or the loss or absence of perception of visual stimuli. This condition may be the result of EYE DISEASES; OPTIC NERVE DISEASES; OPTIC CHIASM diseases; or BRAIN DISEASES affecting the VISUAL PATHWAYS or OCCIPITAL LOBE.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Reuss, S1

Other Studies

1 other study available for oxidopamine and Blindness

ArticleYear
Effects of chemical and surgical ganglionectomy on electrical activity of the pineal gland of male rats.
    Journal of pineal research, 1986, Volume: 3, Issue:1

    Topics: Animals; Blindness; Electric Conductivity; Ganglia, Sympathetic; Hydroxydopamines; Male; Oxidopamine

1986